You are here

Mol Cancer Res DOI:10.1158/1541-7786.MCR-18-0963

MCL1 and DEDD Promote Urothelial Carcinoma Progression.

Publication TypeJournal Article
Year of Publication2019
AuthorsHong, AL, Guerriero, JL, Doshi, MB, Kynnap, BD, Kim, WJun, Schinzel, AC, Modiste, R, Schlauch, AJ, Adam, RM, Kwiatkowski, DJ, Beroukhim, R, Letai, A, Rosenberg, JE, Hahn, WC
JournalMol Cancer Res
Date Published2019 Feb 18
ISSN1557-3125
Abstract

Focal amplification of chromosome 1q23.3 in patients with advanced primary or relapsed urothelial carcinomas is associated with poor survival. We interrogated chromosome 1q23.3 and the nearby focal amplicon 1q21.3, as both are associated with increased lymph node disease in patients with urothelial carcinoma. Specifically, we assessed whether the oncogene that resides in 1q21.3 and the genes that reside in the 1q23.3 amplicon were required for the proliferation or survival of urothelial carcinoma. We observed that suppressing MCL1 or the death effector domain-containing protein (DEDD) in the cells that harbor amplifications of 1q21.3 or 1q23.3, respectively, inhibited cell proliferation. We also found that overexpression of MCL1 or DEDD increased anchorage independence growth and increased experimental metastasis in the nonamplified urothelial carcinoma cell line, RT112. The expression of MCL1 confers resistance to a range of apoptosis inducers, while the expression of DEDD led to resistance to TNFα-induced apoptosis. These observations identify and as genes that contribute to aggressive urothelial carcinoma. These studies identify and as genes that contribute to aggressive urothelial carcinomas.

DOI10.1158/1541-7786.MCR-18-0963
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30777879?dopt=Abstract

Alternate JournalMol. Cancer Res.
PubMed ID30777879
Grant ListU01 CA176058 / CA / NCI NIH HHS / United States